Focused On-demand Library for AN1-type zinc finger protein 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Associated with PRK1 protein; Zinc finger A20 domain-containing protein 3

Alternative UPACC:

Q6FIF0; D3DW92; D3DW94; O95792; Q9BQF7; Q9GZY3


AN1-type zinc finger protein 6, also known as Associated with PRK1 protein and Zinc finger A20 domain-containing protein 3, plays a crucial role in cellular processes. It regulates TNF-alpha induced NF-kappa-B activation and apoptosis, modulates 'Lys-48'-linked polyubiquitination status of TRAF2, and is involved in peroxisomal protein import via interaction with PEX5 and PEX6. Its activity is essential for maintaining cellular homeostasis and responding to stress signals.

Therapeutic significance:

Understanding the role of AN1-type zinc finger protein 6 could open doors to potential therapeutic strategies. Its involvement in NF-kappa-B activation, apoptosis, and protein import into peroxisomes highlights its importance in cellular regulation and stress response, making it a potential target for drug discovery efforts aimed at treating diseases linked to these pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.